Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of multiple myeloma by 2014 IMWG criteria and have been recommended to undergo HDM + ASCT as a standard-of-care therapy for their multiple myeloma.~* Subjects must have adequate vital organ function and functional status for HDM + ASCT~* Subjects must have collected and cryopreserved ≥4x106 hematopoietic stem cells per kg of actual body weight that are suitable for use in autologous stem cell transplantation in the judgment of the investigator.~* At the time of enrollment, subjects must have had at least a partial response, as defined by IMWG criteria and in comparison to baseline/pre-treatment parameters, to an induction regimen containing lenalidomide and/or bortezomib.~* Subjects must have measurable disease according to one of the following criteria:~  1. Serum M-spike ≥0.1 g/dl~ 2. Urine M-spike \>200 mg in a 24-hour urine collection~ 3. Involved serum free light chain above the upper limit of normal and a serum free light chain ratio outside the normal range.~* At the time of enrollment, subjects must be within 12 months of the first dose of initial/induction therapy, and the anticipated day of ASCT must be within 12 months of the first dose of initial/induction therapy~Exclusion Criteria:~* Prior allogeneic or autologous hematopoietic stem cell transplant~* Current active infections, including HIV and hepatitis C and B~* Autoimmune disease requiring ongoing immunosuppressive therapy.~* History of atrial fibrillation or flutter, including paroxysmal atrial fibrillation or flutter.~* History of transient ischemic attack or stroke.~* At the time of enrollment, subjects must not have required multi-agent continuous-infusion cytotoxic chemotherapy (e.g., regimens such as D-PACE) as part of their initial/induction therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- HDM+ASCT (Type: ACTIVE_COMPARATOR): Standard of care; High dose Melphalan + Autologous Stem Cell Transplantation
- BI-505 (Type: EXPERIMENTAL): Biweekly infusions of BI-505 in addition to High dose Melphalan + Autologous Stem Cell Transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).